Previous 10 | Next 10 |
Compugen (CGEN) announces that the first patient has been dosed in the cohort expansion arm of the Phase 1/2 study evaluating the triple combination of COM701, with Bristol Myers Squibb's Opdivo (nivolumab) and investigational anti-TIGIT antibody, BMS-986207.CGEN shares down 2% premarket...
Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207 - This study evaluates Compugen's three-pathway hypothesis with the triple blockade of PVRIG, TIGIT and PD1, stren...
Compugen Ltd. (NASDAQ:CGEN) traded today at a new 52-week low of $6.64. So far today approximately 216,000 shares have been exchanged, as compared to an average 30-day volume of 1 million shares. Compugen Ltd is a therapeutic discovery company. It is involved in the business of using its...
Compugen Ltd. (NASDAQ:CGEN) traded at a new 52-week low today of $6.70. So far today approximately 216,000 shares have been exchanged, as compared to an average 30-day volume of 1 million shares. Compugen Ltd is a therapeutic discovery company. It is involved in the business of using its...
Compugen (CGEN) announces that the first patient has been dosed in its Phase 1 clinical study evaluating the dual combination of COM902 and COM701, in patients with advanced malignancies who have exhausted all available standard therapies.The COM902 monotherapy dose escalation arm of this Pha...
Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies Combination study evaluates dual blockade of PVRIG and TIGIT, parallel and distinct DNAM axis checkpoint pathways Phase 1 COM902 monotherapy dose escalation ...
Compugen to Release Second Quarter 2021 Results on Wednesday, July 28, 2021 PR Newswire HOLON, Israel , July 14, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive targe...
The following slide deck was published by Compugen Ltd. in conjunction with this event. For further details see: Compugen (CGEN) Presents At TIGIT Pathway:Deep Dive in Cancer Immunotherapy Targets - Slideshow
The first patient has been dosed in Compugen's (CGEN) combination expansion cohort of its Phase 1 trial evaluating COM701, an anti-PVRIG antibody, in combination with Bristol Myers Squibb's (BMY) Opdivo (nivolumab).The indications for the combination therapy expansion cohort, ovarian, breast,...
Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study - Study builds upon signals of durable antitumor activity in extensively pretreated patients, including a confirmed complete response in the dose escalation arm - Biomarker-inform...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...